BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/13/2026 8:28:15 AM | Browse: 29 | Download: 85
 |
Received |
|
2025-09-18 02:32 |
|
Peer-Review Started |
|
2025-09-18 02:33 |
|
First Decision by Editorial Office Director |
|
2025-11-10 07:09 |
|
Return for Revision |
|
2025-11-10 07:09 |
|
Revised |
|
2025-11-22 16:28 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-25 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-25 07:32 |
|
Articles in Press |
|
2025-12-25 07:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-26 10:35 |
|
Publish the Manuscript Online |
|
2026-03-13 08:28 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Review |
| Article Title |
Viral hepatitis after liver transplantation: A brief overview
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dibya Lochan Praharaj, Suprabhat Giri, Anil Chandra Anand, Bipadabhanjan Mallick, Preetam Nath, Saroj Kanta Sahu, Bramhadatta Pattnaik, Subrat Kumar Acharya and Yogesh Kumar Chawla |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Anil Chandra Anand, Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, KIIT Campus, Patia, Bhubaneswar 751024, Odisha, India. anilcanand@gmail.com |
| Key Words |
Viral hepatitis; Hepatotropic virus; Liver transplantation; Cytomegalovirus disease; Post-transplant lymphoproliferative disorders |
| Core Tip |
Effective management of viral hepatitis after liver transplantation hinges on early diagnosis, vigilant monitoring, and timely antiviral therapy. For hepatitis B virus, nucleos(t)ide analogues with high genetic barriers to resistance (e.g., entecavir, tenofovir alefnamide/tenofovir disoproxyl fumarate) are preferred, often with short-term hepatitis B immunoglobulin in high-risk patients. Directly acting antivirals have revolutionized treatment of patients with hepatitis C virus infection. Though timing of treatment must balance the baseline model for end stage liver disease score and graft outcomes. Hepatitis E virus infection should be suspected in unexplained graft dysfunction; ribavirin is effective when reduction of immunosupression fails. Recurrence with hepatitis D virus infection is rare if hepatitis B virus is well controlled. Infection with cytomegalovirus and Epstein-Barr virus require prophylaxis, pre-emptive monitoring, and individualized immunosuppression adjustment to reduce risk of post-transplant lymphoproliferative disorder (related to Epstein-Barr virus infection) and graft loss. |
| Publish Date |
2026-03-13 08:28 |
| Citation |
Praharaj DL, Giri S, Anand AC, Mallick B, Nath P, Sahu SK, Pattnaik B, Acharya SK, Chawla YK. Viral hepatitis after liver transplantation: A brief overview. World J Virol 2026; 15(1): 114321 |
| URL |
https://www.wjgnet.com/2220-3249/full/v15/i1/114321.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v15.i1.114321 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
